9 recruiting, 5 unknown, 3 completed, 3 not yet recruiting. 8 Early Phase 1, 7 Phase 1, 5 Not applicable, 1 Phase 2, 1 Phase 4.
Follow He Huang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs) JY231 Injection - Autoimmune Diseases | Not applicable | Not yet recruiting | He Huang | 45 | 2025-03-31 | 2025-03-21 |
| JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia JY231 Injection - B-ALL | Not applicable | Not yet recruiting | He Huang | 24 | 2025-03-31 | 2025-03-30 |
| JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma JY231 Injection - B-Non Hodgkin Lymphoma | Not applicable | Not yet recruiting | He Huang | 24 | 2025-03-01 | 2025-03-17 |
| CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection - Lupus Nephritis | Early Phase 1 | Recruiting | He Huang | 9 | 2025-01-31 | 2025-01-21 |
| A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia CAR-T cells（ chimeric antigen receptor T cells） - Relapsed/Refractory Acute Myeloid Leukemia(AML) | Phase 1 | Suspended | He Huang | 24 | 2025-01-08 | 2025-11-24 |
| RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR Venetoclax, Allogeneic transplant - Acute Myeloid Leukemia | Phase 4 | Recruiting | He Huang | 118 | 2024-07-17 | 2024-08-26 |
| Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research Metabolically Armed CD19 CAR-T cells - Diffuse Large B-cell Lymphoma | Early Phase 1 | Recruiting | He Huang | 18 | 2023-11-16 | 2025-09-19 |
| A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I LY-M001 Injection - Gaucher Disease Type I | Not applicable | Recruiting | He Huang | 3 | 2023-11-15 | 2025-02-14 |
| A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma DeepTag-GPRC5D Targeted CAR T-cells - Relapse/Refractory Multiple Myeloma | Phase 1 | Recruiting | He Huang | 40 | 2023-10-20 | 2023-10-16 |
| CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms | Early Phase 1 | Completed | He Huang | 20 | 2023-02-09 | 2024-11-21 |
| Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Busulfan (Busulfex), Cyclophosphamide (CTX), Fludarabine (Fludara) - Hematologic Disease | Phase 1 | Recruiting | He Huang | 29 | 2022-08-04 | 2026-06-09 |
| Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation Busulfan (Busulfex), Cyclophosphamide (CTX), Fludarabine (Fludara) - Hematologic Diseases | Phase 1 | Recruiting | He Huang | 29 | 2022-08-04 | 2025-02-05 |
| A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma RD14-01 cell infusion - Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma | Early Phase 1 | Unknown | He Huang | 18 | 2022-07-05 | 2022-07-11 |
| Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia ThisCART19A - AIDS Related Lymphoma and Lympholeukemia | Phase 1 | Unknown | He Huang | 18 | 2022-03-18 | 2022-04-22 |
| A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies CTA30X - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | Early Phase 1 | Completed | He Huang | 3 | 2020-12-29 | 2025-01-24 |
| Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma GC022F CAR-T cells - Relapsed and Refractory, Lymphoid Hematological Malignancies | Phase 1 / Phase 2 | Unknown | He Huang | 18 | 2020-11-20 | 2020-11-13 |
| RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies RD13-01 cell infusion - Hematologic Malignancies | Phase 1 | Completed | He Huang | 12 | 2020-09-10 | 2022-01-25 |
| Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study Peripheral blood mononuclear cell apheresis - Peripheral Blood Mononuclear Cell | Not applicable | Unknown | He Huang | 50 | 2020-06-18 | 2020-06-26 |
| A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy CT-RD06 - Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Early Phase 1 | Unknown | He Huang | 72 | 2020-02-05 | 2020-02-21 |
| A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy CTA101 - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | Early Phase 1 | Recruiting | He Huang | 72 | 2020-01-08 | 2020-12-28 |
Showing 20 of 21. Sign in to see all of them.
Hematologic Diseases (3) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Recurrence (3) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Large B-Cell, Diffuse (2) · Autoimmune Diseases (1) · Gaucher Disease (1) · Lupus Nephritis (1) · Lymphoma, AIDS-Related (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Multiple Myeloma (1) · Neoplasms (1)
Busulfan (2) · Cyclophosphamide (2) · Semustine (2) · fludarabine (2) · fludarabine phosphate (2) · Transplantation, Homologous (1) · venetoclax (1)
China (20)
PMID 14578207, PMID 1603628, PMID 17230068, PMID 23520473, PMID 24488939, PMID 25409372, PMID 28621801, PMID 29719368, PMID 30622983, PMID 32146279, PMID 32687450, PMID 32786187, PMID 33067633, PMID 34614506, PMID 35704787, PMID 35857660, PMID 36151216, PMID 36863709, PMID 38657244, PMID 42490071